GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

PR Newswire associated2

PR Newswire associated3

Tags

GemVax-&-KAEL

More Like This

PR Newswire associated1

Seoul National University Bundang Hospital Establishes the first "International PSP Research and Treatment Center" in Korea

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens

Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial

Ferrer's pharmaceutical production plant in Sant Cugat del Vallés, Barcelona, Spain.

Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)

Immunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C